- Home
- FND vs INAB Comparison
FND vs INAB Comparison
Compare FND & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FND | INAB |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 22.9M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FND | INAB |
|---|---|---|
| Price | $50.65 | $1.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 1 |
| Target Price | ★ $77.88 | $6.00 |
| AVG Volume (30 Days) | ★ 2.2M | 65.0K |
| Earning Date | 04-30-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.05 | N/A |
| EPS | ★ 1.92 | N/A |
| Revenue | ★ $4,684,088,000.00 | N/A |
| Revenue This Year | $7.56 | N/A |
| Revenue Next Year | $7.78 | N/A |
| P/E Ratio | $25.77 | ★ N/A |
| Revenue Growth | ★ 5.12 | N/A |
| 52 Week Low | $49.23 | $0.12 |
| 52 Week High | $92.41 | $4.20 |
Technical Indicators
Market Signals| Indicator | FND | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 32.79 | 41.58 |
| Support Level | N/A | $1.17 |
| Resistance Level | $64.23 | $2.14 |
| Average True Range (ATR) | 2.25 | 0.19 |
| MACD | -0.18 | -0.04 |
| Stochastic Oscillator | 13.43 | 18.42 |
Price Performance
Historical ComparisonAbout FND Floor & Decor Holdings Inc.
Floor & Decor Holdings Inc operates as a specialty retailer in the hard surface flooring market. Its stores offer a range of tile, wood, laminate, and natural stone flooring products, as well as decorative and installation accessories at everyday low prices. It appeals to a variety of customers including professional installers, commercial businesses, Do It Yourself (DIY) customers, and customers who buy the products for professional installation. Geographically, the group has a presence in the United States region and also offers its product through an e-commerce site. The company segments include retail segment and others.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.